SCHEMBL21541865

SCHEMBL21541865

[c]1ncn2cnc3ccccc3c12

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.37
HPGD P15428 1/20 0.37
HSD17B10 Q99714 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.36
HTT P42858 1/20 0.36
RAB9A P51151 2/20 0.35
STAT3 P40763 1/20 0.35
GPR3 P46089 1/20 0.34
NPC1 O15118 1/20 0.33
USP5 P45974 1/20 0.33
NCF1 P14598 1/20 0.33
GAA P10253 1/20 0.33
PKM P14618 1/20 0.33
PI4KA P42356 1/20 0.33
PI4K2B Q8TCG2 1/20 0.33
PI4K2A Q9BTU6 1/20 0.33
PI4KB Q9UBF8 1/20 0.33
PDE4A P27815 1/20 0.33
PDE4B Q07343 1/20 0.33
PDE4C Q08493 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4719137 0.70 IDO1 (0.47) KDM4EHPGDHSD17B10SMN1; SMN2RAB9A
SCHEMBL2511897 0.66 KDM4E (0.42) KDM4EHPGDHSD17B10SMN1; SMN2RAB9A
SCHEMBL4788149 0.65 KDM4E (0.46) KDM4EHPGDHSD17B10SMN1; SMN2HTT
SCHEMBL1370906 0.64 KDM4E (0.45) KDM4EHPGDHSD17B10SMN1; SMN2RAB9A
SCHEMBL30494729 0.64 KDM4E (0.51) KDM4EHPGDHSD17B10SMN1; SMN2HTT
SCHEMBL29485626 0.64 KDM4E (0.45) KDM4EHPGDHSD17B10SMN1; SMN2RAB9A
SCHEMBL4792073 0.64 IDO1 (0.53) KDM4EHPGDHSD17B10SMN1; SMN2HTT
SCHEMBL19500966 0.61 KDM4E (0.45) KDM4EHPGDHSD17B10SMN1; SMN2RAB9A
SCHEMBL18922383 0.61 KDM4E (0.53) KDM4ESMN1; SMN2HTTRAB9ANPC1
SCHEMBL11083282 0.61 KDM4E (0.35) KDM4EHPGDHSD17B10SMN1; SMN2RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3567041-B1 SUBSTITUTED FUSED HETEROARYL COMPOUND SERVING AS A KINASE INHIBITOR, AND APPLICATIONS THEREOF IMPACT THERAPEUTICS SHANGHAI INC (CN) 2023-12-27 EP disclosed
EP-3567041-A9 SUBSTITUTED FUSED HETEROARYL COMPOUND SERVING AS A KINASE INHIBITOR, AND APPLICATIONS THEREOF Impact Therapeutics (Shanghai), Inc (CN) 2022-04-20 EP disclosed
US-10874670-B2 Substituted fused heteroaromatic compounds as kinase inhibitors and the use thereof IMPACT THERAPEUTICS, INC. (CN) 2020-12-29 US disclosed
EP-3567041-A1 SUBSTITUTED FUSED HETEROARYL COMPOUND SERVING AS A KINASE INHIBITOR, AND APPLICATIONS THEREOF Impact Therapeutics, Inc (CN) 2019-11-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10874670-B2 Substituted fused heteroaromatic compounds as kinase inhibitors and the use thereof CHEK1, CHEK2, CDK1 KDM4E 372/4885HPGD 2373/4885HSD17B10 2898/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.